Syremis Therapeutics Launches With $165 Million To Develop Best-In-Class Medicines For Mental Health Conditions

Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to treat mental health, announced its launch with $165 million financing, according to a recent announcement. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, Google Ventures, QVT, and Pictet, will support the advancement of Syremis’ pipeline through clinical proof of concept.

Syremis’ lead program, ST-905, is a dual muscarinic agonist under development for schizophrenia and other neuropsychiatric conditions and is currently in Phase 1. The molecule’s differentiated potency and favorable pharmaceutical properties position it as a potential . . .